1
|
Recent Advances in the Endogenous Brain Renin-Angiotensin System and Drugs Acting on It. J Renin Angiotensin Aldosterone Syst 2021; 2021:9293553. [PMID: 34925551 PMCID: PMC8651430 DOI: 10.1155/2021/9293553] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2021] [Revised: 10/14/2021] [Accepted: 10/23/2021] [Indexed: 12/22/2022] Open
Abstract
The RAS (renin-angiotensin system) is the part of the endocrine system that plays a prime role in the control of essential hypertension. Since the discovery of brain RAS in the seventies, continuous efforts have been put by the scientific committee to explore it more. The brain has shown the presence of various components of brain RAS such as angiotensinogen (AGT), converting enzymes, angiotensin (Ang), and specific receptors (ATR). AGT acts as the precursor molecule for Ang peptides—I, II, III, and IV—while the enzymes such as prorenin, ACE, and aminopeptidases A and N synthesize it. AT1, AT2, AT4, and mitochondrial assembly receptor (MasR) are found to be plentiful in the brain. The brain RAS system exhibits pleiotropic properties such as neuroprotection and cognition along with regulation of blood pressure, CVS homeostasis, thirst and salt appetite, stress, depression, alcohol addiction, and pain modulation. The molecules acting through RAS predominantly ARBs and ACEI are found to be effective in various ongoing and completed clinical trials related to cognition, memory, Alzheimer's disease (AD), and pain. The review summarizes the recent advances in the brain RAS system highlighting its significance in pathophysiology and treatment of the central nervous system-related disorders.
Collapse
|
2
|
Zóia Miltenburg T, Uana da Silva M, Bosch G, Vasconcellos RS. Effects of enzymatically hydrolysed poultry byproduct meal in extruded diets on serum angiotensin-converting enzyme activity and aldosterone in cats. Arch Anim Nutr 2020; 75:64-77. [PMID: 33307796 DOI: 10.1080/1745039x.2020.1849899] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Several peptides found in hydrolysed poultry byproduct meal can inhibit angiotensin-converting enzyme (ACE) activity, a property that indicates potential antihypertensive and health-promoting effects. This study aimed to assess the effects of extruded diets containing enzymatically hydrolysed poultry byproduct meal (HPM) on cat serum ACE activity and aldosterone (ALD) concentration, nutrient digestibility, and faecal characteristics. On the basis of a preliminary in vitro ACE inhibitory activity assay, a commercial HPM and a commercial conventional poultry byproduct meal (CPM) were selected for further investigation. Two isoenergetic and isonitrogenous diets were formulated: CPM diet (25.7% CPM) and HPM diet (24.7% HPM). In trial 1, the effect of diet on serum ACE activity and ALD concentration was evaluated using 8 healthy cats (4 female and 4 male, 4.1 ± 0.38 kg BW) in a crossover design, with 5 d of adaptation and blood collection on d 6. In trial 2, apparent total tract digestibility and faecal characteristics were evaluated using 12 cats (6 female and 6 male, 4.0 ± 0.72 kg BW) in a completely randomised design. Serum ACE and ALD were analysed using a mixed model, with diet as the fixed effect and cat as the random effect. Data from trial 2 were subjected to analysis of variance, and means were compared by Tukey's test. In vitro ACE inhibitory activity of HPM (90.4%) was higher than that of CPM (52.0%). Cats fed the HPM diet tended to have lower serum ACE activity than those fed the CPM diet (126 versus 142 U/l, p = 0.09). Serum ALD was not influenced by diet. Diets had similar digestibility values, and faecal consistency scores tended to be higher (firmer faeces) in cats fed the CPM diet than in cats fed the HPM diet (4.6 versus 4.0, p = 0.09). Inclusion of HPM in extruded diets may reduce cat serum ACE activity and promote good faecal consistency without affecting digestibility. Further investigations are needed to explore the potential health benefits of HPM in hypertensive cats.
Collapse
Affiliation(s)
- Tânia Zóia Miltenburg
- Department of Animal Science, State University of Maringá , Maringá, Brazil.,Animal Nutrition Group, Wageningen University and Research , Wageningen, Netherlands
| | | | - Guido Bosch
- Animal Nutrition Group, Wageningen University and Research , Wageningen, Netherlands
| | | |
Collapse
|
3
|
Semis M, Gugiu GB, Bernstein EA, Bernstein KE, Kalkum M. The Plethora of Angiotensin-Converting Enzyme-Processed Peptides in Mouse Plasma. Anal Chem 2019; 91:6440-6453. [PMID: 31021607 DOI: 10.1021/acs.analchem.8b03828] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Angiotensin-converting enzyme (ACE) converts angiotensin I into the potent vasoconstrictor angiotensin II, which regulates blood pressure. However, ACE activity is also essential for other physiological functions, presumably through processing of peptides unrelated to angiotensin. The goal of this study was to identify novel natural substrates and products of ACE through a series of mass-spectrometric experiments. This included comparing the ACE-treated and untreated plasma peptidomes of ACE-knockout (KO) mice, validation with select synthetic peptides, and a quantitative in vivo study of ACE substrates in mice with distinct genetic ACE backgrounds. In total, 244 natural peptides were identified ex vivo as possible substrates or products of ACE, demonstrating high promiscuity of the enzyme. ACE prefers to cleave substrates with Phe or Leu at the C-terminal P2' position and Gly in the P6 position. Pro in P1' and Iso in P1 are typical residues in peptides that ACE does not cleave. Several of the novel ACE substrates are known to have biological activities, including a fragment of complement C3, the spasmogenic C3f, which was processed by ACE ex vivo and in vitro. Analyses with N-domain-inactive (NKO) ACE allowed clarification of domain selectivity toward substrates. The in vivo ACE-substrate concentrations in WT, transgenic ACE-KO, NKO, and CKO mice correspond well with the in vitro observations in that higher levels of the ACE substrates were observed when the processing domain was knocked out. This study highlights the vast extent of ACE promiscuity and provides a valuable platform for further investigations of ACE functionality.
Collapse
Affiliation(s)
- Margarita Semis
- Department of Molecular Imaging and Therapy, Diabetes and Metabolism Research Institute , Beckman Research Institute of the City of Hope , Duarte , California 91010 , United States
| | - Gabriel B Gugiu
- Department of Molecular Imaging and Therapy, Diabetes and Metabolism Research Institute , Beckman Research Institute of the City of Hope , Duarte , California 91010 , United States.,Mass Spectrometry & Proteomics Core Facility , Beckman Research Institute of the City of Hope , Duarte , California 91010 , United States
| | - Ellen A Bernstein
- Departments of Biomedical Sciences, Pathology and Laboratory Medicine , Cedars-Sinai Medical Center , Los Angeles , California 90048 , United States
| | - Kenneth E Bernstein
- Departments of Biomedical Sciences, Pathology and Laboratory Medicine , Cedars-Sinai Medical Center , Los Angeles , California 90048 , United States
| | - Markus Kalkum
- Department of Molecular Imaging and Therapy, Diabetes and Metabolism Research Institute , Beckman Research Institute of the City of Hope , Duarte , California 91010 , United States.,Mass Spectrometry & Proteomics Core Facility , Beckman Research Institute of the City of Hope , Duarte , California 91010 , United States
| |
Collapse
|
4
|
Li HJ, Zheng CR, Chen GZ, Qin J, Zhang JH, Yu J, Zhang EH, Huang L. Budesonide, but not dexamethasone, blunted the response of aldosterone to renin elevation by suppressing angiotensin converting enzyme upon high-altitude exposure. J Renin Angiotensin Aldosterone Syst 2016; 17:1470320316653867. [PMID: 27317302 PMCID: PMC5843924 DOI: 10.1177/1470320316653867] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2015] [Accepted: 02/12/2016] [Indexed: 11/16/2022] Open
Abstract
INTRODUCTION Inhaled budesonide is a novel approach to prevent acute mountain sickness (AMS). However, its mechanism is not completely understood. We aimed to investigate the effects of budesonide and dexamethasone on renin-angiotensin-aldosterone system in AMS prevention. MATERIALS AND METHODS Data were obtained from a randomised controlled trial including 138 participants. The participants were randomly assigned to receive budesonide, dexamethasone or placebo as prophylaxis before they travelled to 3450 m altitude from 400 m by car. Their plasma concentrations of renin, angiotensin-converting enzyme (ACE) and aldosterone were measured at both altitudes. RESULTS All parameters were comparable among the three groups at 400 m. After high-altitude exposure of 3450, renin in all groups increased significantly; the ACE, aldosterone concentrations, as well as the aldosterone/renin ratio, rose markedly in the dexamethasone and placebo groups but not in the budesonide group. Moreover, the aldosterone/renin ratio correlated closely with ACE concentration. CONCLUSIONS Upon acute high-altitude exposure, budesonide, but not dexamethasone, blunted the response of aldosterone to renin elevation by suppressing angiotensin converting enzyme.
Collapse
Affiliation(s)
- Hui-Jie Li
- Institute of Cardiovascular Science, Third Military Medical University, China
| | - Cheng-Rong Zheng
- Institute of Cardiovascular Science, Third Military Medical University, China Department of Cardiovascular Science, The General Hospital of the People's Liberation Army (PLA) Rocket Force, China
| | - Guo-Zhu Chen
- Institute of Cardiovascular Science, Third Military Medical University, China PLA Institute of Cardiovascular Disease, China
| | - Jun Qin
- Institute of Cardiovascular Science, Third Military Medical University, China PLA Institute of Cardiovascular Disease, China
| | - Ji-Hang Zhang
- Institute of Cardiovascular Science, Third Military Medical University, China PLA Institute of Cardiovascular Disease, China
| | - Jie Yu
- Institute of Cardiovascular Science, Third Military Medical University, China PLA Institute of Cardiovascular Disease, China
| | - En-Hao Zhang
- Institute of Cardiovascular Science, Third Military Medical University, China
| | - Lan Huang
- Institute of Cardiovascular Science, Third Military Medical University, China PLA Institute of Cardiovascular Disease, China
| |
Collapse
|
5
|
Claflin KE, Grobe JL. Control of energy balance by the brain renin-angiotensin system. Curr Hypertens Rep 2016; 17:38. [PMID: 25833461 DOI: 10.1007/s11906-015-0549-x] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The renin-angiotensin system (RAS) exists as a circulating hormone system but it is also used by various tissues of the body, including the brain, as a paracrine signaling mechanism. The local brain version of the RAS is mechanistically involved in fluid balance and blood pressure control, and there is growing appreciation for a role of the brain RAS in the control of energy balance. Here, we review major evidence for the control of energy balance by the brain RAS; outline the current understanding of the RAS components, targets, and mechanisms involved; and highlight some major questions that currently face the field.
Collapse
Affiliation(s)
- Kristin E Claflin
- Department of Pharmacology, Center for Hypertension Research, Obesity Research & Education Initiative, François M. Abboud Cardiovascular Research Center, and Fraternal Order of Eagles' Diabetes Research Center, University of Iowa, 51 Newton Rd., 2-307 BSB, Iowa City, IA, 52242, USA
| | | |
Collapse
|
6
|
Arcanjo DDR, Vasconcelos AG, Comerma-Steffensen SG, Jesus JR, Silva LP, Pires OR, Costa-Neto CM, Oliveira EB, Migliolo L, Franco OL, Restini CBA, Paulo M, Bendhack LM, Bemquerer MP, Oliveira AP, Simonsen U, Leite JRDSDA. A Novel Vasoactive Proline-Rich Oligopeptide from the Skin Secretion of the Frog Brachycephalus ephippium. PLoS One 2015; 10:e0145071. [PMID: 26661890 PMCID: PMC4682775 DOI: 10.1371/journal.pone.0145071] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2015] [Accepted: 11/29/2015] [Indexed: 01/13/2023] Open
Abstract
Proline-rich oligopeptides (PROs) are a large family which comprises the bradykinin-potentiating peptides (BPPs). They inhibit the activity of the angiotensin I-converting enzyme (ACE) and have a typical pyroglutamyl (Pyr)/proline-rich structure at the N- and C-terminus, respectively. Furthermore, PROs decrease blood pressure in animals. In the present study, the isolation and biological characterization of a novel vasoactive BPP isolated from the skin secretion of the frog Brachycephalus ephippium is described. This new PRO, termed BPP-Brachy, has the primary structure WPPPKVSP and the amidated form termed BPP-BrachyNH2 inhibits efficiently ACE in rat serum. In silico molecular modeling and docking studies suggest that BPP-BrachyNH2 is capable of forming a hydrogen bond network as well as multiple van der Waals interactions with the rat ACE, which blocks the access of the substrate to the C-domain active site. Moreover, in rat thoracic aorta BPP-BrachyNH2 induces potent endothelium-dependent vasodilatation with similar magnitude as captopril. In DAF-FM DA-loaded aortic cross sections examined by confocal microscopy, BPP-BrachyNH2 was found to increase the release of nitric oxide (NO). Moreover, BPP-BrachyNH2 was devoid of toxicity in endothelial and smooth muscle cell cultures. In conclusion, the peptide BPP-BrachyNH2 has a novel sequence being the first BPP isolated from the skin secretion of the Brachycephalidae family. This opens for exploring amphibians as a source of new biomolecules. The BPP-BrachyNH2 is devoid of cytotoxicity and elicits endothelium-dependent vasodilatation mediated by NO. These findings open for the possibility of potential application of these peptides in the treatment of endothelial dysfunction and cardiovascular diseases.
Collapse
Affiliation(s)
- Daniel Dias Rufino Arcanjo
- Núcleo de Pesquisa em Biodiversidade e Biotecnologia–BIOTEC, Campus Ministro Reis Velloso–CMRV, Universidade Federal do Piauí –UFPI, Parnaíba, PI, Brazil
- Laboratório de Farmacologia Cardiovascular–LFC, Núcleo de Pesquisas em Plantas Medicinais–NPPM, Universidade Federal do Piauí –UFPI, Teresina, PI, Brazil
| | - Andreanne Gomes Vasconcelos
- Núcleo de Pesquisa em Biodiversidade e Biotecnologia–BIOTEC, Campus Ministro Reis Velloso–CMRV, Universidade Federal do Piauí –UFPI, Parnaíba, PI, Brazil
| | | | - Joilson Ramos Jesus
- Núcleo de Pesquisa em Biodiversidade e Biotecnologia–BIOTEC, Campus Ministro Reis Velloso–CMRV, Universidade Federal do Piauí –UFPI, Parnaíba, PI, Brazil
| | - Luciano Paulino Silva
- Laboratório de Espectrometria de Massa, EMBRAPA Recursos Genéticos e Biotecnologia, Brasília, DF, Brazil
| | - Osmindo Rodrigues Pires
- Laboratório de Toxinologia, Instituto de Ciências Biológicas–ICB, Universidade de Brasília–UnB, Brasília, DF, Brazil
| | - Claudio Miguel Costa-Neto
- Departamento de Bioquímica e Imunologia, Faculdade de Medicina de Ribeirão Preto–FMRP, Universidade de São Paulo–USP, Ribeirão Preto, SP, Brazil
| | - Eduardo Brandt Oliveira
- Departamento de Bioquímica e Imunologia, Faculdade de Medicina de Ribeirão Preto–FMRP, Universidade de São Paulo–USP, Ribeirão Preto, SP, Brazil
| | - Ludovico Migliolo
- Centro de Análises Proteômicas e Bioquímicas–CAPB, Universidade Católica de Brasília–UCB, Brasília, DF, Brazil
| | - Octávio Luiz Franco
- Centro de Análises Proteômicas e Bioquímicas–CAPB, Universidade Católica de Brasília–UCB, Brasília, DF, Brazil
| | | | - Michele Paulo
- Departamento de Física e Química, Faculdade de Ciências Farmacêuticas de Ribeirão Preto–FCFRP, Universidade de São Paulo–USP, Ribeirão Preto, SP, Brazil
| | - Lusiane Maria Bendhack
- Departamento de Física e Química, Faculdade de Ciências Farmacêuticas de Ribeirão Preto–FCFRP, Universidade de São Paulo–USP, Ribeirão Preto, SP, Brazil
| | - Marcelo Porto Bemquerer
- Laboratório de Espectrometria de Massa, EMBRAPA Recursos Genéticos e Biotecnologia, Brasília, DF, Brazil
| | - Aldeidia Pereira Oliveira
- Laboratório de Farmacologia Cardiovascular–LFC, Núcleo de Pesquisas em Plantas Medicinais–NPPM, Universidade Federal do Piauí –UFPI, Teresina, PI, Brazil
| | - Ulf Simonsen
- Pulmonary and Cardiovascular Pharmacology, Department of Biomedicine, Aarhus University, Aarhus, Denmark
| | - José Roberto de Souza de Almeida Leite
- Núcleo de Pesquisa em Biodiversidade e Biotecnologia–BIOTEC, Campus Ministro Reis Velloso–CMRV, Universidade Federal do Piauí –UFPI, Parnaíba, PI, Brazil
- * E-mail:
| |
Collapse
|
7
|
Santos CF, Morandini AC, Dionísio TJ, Faria FA, Lima MC, Figueiredo CM, Colombini-Ishikiriama BL, Sipert CR, Maciel RP, Akashi AP, Souza GP, Garlet GP, Rodini CO, Amaral SL, Becari C, Salgado MC, Oliveira EB, Matus I, Didier DN, Greene AS. Functional Local Renin-Angiotensin System in Human and Rat Periodontal Tissue. PLoS One 2015; 10:e0134601. [PMID: 26244896 PMCID: PMC4526652 DOI: 10.1371/journal.pone.0134601] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2015] [Accepted: 07/12/2015] [Indexed: 12/28/2022] Open
Abstract
The initiation or progression of periodontitis might involve a local renin-angiotensin system (RAS) in periodontal tissue. The aim of this study was to further characterize the local RAS in human and rat periodontal tissues between healthy and periodontally-affected tissue. Components of the RAS were investigated using in vitro, ex vivo and in vivo experiments involving both human and Wistar rat periodontium. Although not upregulated when challenged with P. gingivalis-lipopolysaccharide, human gingival and periodontal ligament fibroblasts expressed RAS components. Likewise, healthy and inflamed human gingiva expressed RAS components, some of which were shown to be functional, yet no differences in expression were found between healthy and diseased gingiva. However, in inflamed tissue the immunoreactivity was greater for the AT1R compared to AT2R in fibroblasts. When compared to healthy tissue, ACE activity was increased in human gingiva from volunteers with gingivitis. Human-gingiva homogenates generated Ang II, Ang 1-9 and Ang 1-7 when incubated with precursors. In gingiva homogenates, Ang II formation from Ang I was nearly abolished only when captopril and chymostatin were combined. Ang 1-7 formation was significantly greater when human gingiva homogenates were incubated with chymostatin alone compared to incubation without any inhibitor, only captopril, or captopril and chymostatin. In rat gingiva, RAS components were also found; their expression was not different between healthy and experimentally induced periodontitis (EP) groups. However, renin inhibition (aliskiren) and an AT1R antagonist (losartan) significantly blocked EP-alveolar-bone loss in rats. Collectively, these data are consistent with the hypothesis that a local RAS system is not only present but is also functional in both human and rat periodontal tissue. Furthermore, blocking AT1R and renin can significantly prevent periodontal bone loss induced by EP in rats.
Collapse
Affiliation(s)
- Carlos F. Santos
- Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru, São Paulo, Brazil
- * E-mail:
| | - Ana C. Morandini
- Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru, São Paulo, Brazil
| | - Thiago J. Dionísio
- Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru, São Paulo, Brazil
| | - Flávio A. Faria
- Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru, São Paulo, Brazil
| | - Marta C. Lima
- Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru, São Paulo, Brazil
| | - Caio M. Figueiredo
- Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru, São Paulo, Brazil
| | | | - Carla R. Sipert
- Department of Restorative Dentistry, School of Dentistry, University of São Paulo, São Paulo, São Paulo, Brazil
| | - Rubens P. Maciel
- Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru, São Paulo, Brazil
| | - Ana P. Akashi
- Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru, São Paulo, Brazil
| | - Gabriela P. Souza
- Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru, São Paulo, Brazil
| | - Gustavo P. Garlet
- Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru, São Paulo, Brazil
| | - Camila O. Rodini
- Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru, São Paulo, Brazil
| | - Sandra L. Amaral
- Department of Physical Education, Science Faculty, São Paulo State University, Bauru, São Paulo, Brazil
| | - Christiane Becari
- School of Medicine of Ribeirão Preto, Riberão Preto, University of São Paulo, Riberão Preto, São Paulo, Brazil
| | - Maria C. Salgado
- School of Medicine of Ribeirão Preto, Riberão Preto, University of São Paulo, Riberão Preto, São Paulo, Brazil
| | - Eduardo B. Oliveira
- School of Medicine of Ribeirão Preto, Riberão Preto, University of São Paulo, Riberão Preto, São Paulo, Brazil
| | - Isaac Matus
- Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America
| | - Daniela N. Didier
- Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America
| | - Andrew S. Greene
- Department of Physiology, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America
| |
Collapse
|
8
|
Speth RC, Carrera EJ, Bretón C, Linares A, Gonzalez-Reiley L, Swindle JD, Santos KL, Schadock I, Bader M, Karamyan VT. Distribution of non-AT1, non-AT2 binding of 125I-sarcosine1, isoleucine8 angiotensin II in neurolysin knockout mouse brains. PLoS One 2014; 9:e105762. [PMID: 25147932 PMCID: PMC4141804 DOI: 10.1371/journal.pone.0105762] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2014] [Accepted: 06/13/2014] [Indexed: 11/18/2022] Open
Abstract
The recent identification of a novel binding site for angiotensin (Ang) II as the peptidase neurolysin (E.C. 3.4.24.16) has implications for the renin-angiotensin system (RAS). This report describes the distribution of specific binding of 125I-Sarcosine1, Isoleucine8 Ang II (125I-SI Ang II) in neurolysin knockout mouse brains compared to wild-type mouse brains using quantitative receptor autoradiography. In the presence of p-chloromercuribenzoic acid (PCMB), which unmasks the novel binding site, widespread distribution of specific (3 µM Ang II displaceable) 125I-SI Ang II binding in 32 mouse brain regions was observed. Highest levels of binding >700 fmol/g initial wet weight were seen in hypothalamic, thalamic and septal regions, while the lowest level of binding <300 fmol/g initial wet weight was in the mediolateral medulla. 125I-SI Ang II binding was substantially higher by an average of 85% in wild-type mouse brains compared to neurolysin knockout brains, suggesting the presence of an additional non-AT1, non-AT2, non-neurolysin Ang II binding site in the mouse brain. Binding of 125I-SI Ang II to neurolysin in the presence of PCMB was highest in hypothalamic and ventral cortical brain regions, but broadly distributed across all regions surveyed. Non-AT1, non-AT2, non-neurolysin binding was also highest in the hypothalamus but had a different distribution than neurolysin. There was a significant reduction in AT2 receptor binding in the neurolysin knockout brain and a trend towards decreased AT1 receptor binding. In the neurolysin knockout brains, the size of the lateral ventricles was increased by 56% and the size of the mid forebrain (−2.72 to +1.48 relative to Bregma) was increased by 12%. These results confirm the identity of neurolysin as a novel Ang II binding site, suggesting that neurolysin may play a significant role in opposing the pathophysiological actions of the brain RAS and influencing brain morphology.
Collapse
Affiliation(s)
- Robert C. Speth
- Department of Pharmaceutical Sciences, Nova Southeastern University, Fort Lauderdale, Florida, United States of America
- Department of Physiology and Functional Genomics, University of Florida, Gainesville, Florida, United States of America
- * E-mail:
| | - Eduardo J. Carrera
- Department of Pharmaceutical Sciences, Nova Southeastern University, Fort Lauderdale, Florida, United States of America
- Farquhar College of Arts and Sciences, Nova Southeastern University, Fort Lauderdale, Florida, United States of America
| | - Catalina Bretón
- Department of Pharmaceutical Sciences, Nova Southeastern University, Fort Lauderdale, Florida, United States of America
- Farquhar College of Arts and Sciences, Nova Southeastern University, Fort Lauderdale, Florida, United States of America
| | - Andrea Linares
- Farquhar College of Arts and Sciences, Nova Southeastern University, Fort Lauderdale, Florida, United States of America
| | - Luz Gonzalez-Reiley
- Farquhar College of Arts and Sciences, Nova Southeastern University, Fort Lauderdale, Florida, United States of America
| | - Jamala D. Swindle
- Farquhar College of Arts and Sciences, Nova Southeastern University, Fort Lauderdale, Florida, United States of America
| | - Kira L. Santos
- Farquhar College of Arts and Sciences, Nova Southeastern University, Fort Lauderdale, Florida, United States of America
- College of Dentistry, University of Florida, Gainesville, Florida, United States of America
| | - Ines Schadock
- Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
| | - Michael Bader
- Max-Delbrück-Center for Molecular Medicine, Berlin, Germany
| | - Vardan T. Karamyan
- Department of Pharmaceutical Sciences, Texas Tech University Health Sciences Center, Amarillo, Texas, United States of America
- Center for Blood-Brain Barrier Research, Texas Tech University Health Sciences Center, Amarillo, Texas, United States of America
| |
Collapse
|
9
|
Ribeiro MS, Dellalibera-Joviliano R, Becari C, Teixeira FR, Araujo PV, Piccinato CE, Campos CP, Evora PRB, Joviliano EE. Characterization of the Kallikrein-kinin System, Metalloproteinases, and Their Tissue Inhibitors in the In-stent Restenosis after Peripheral Percutaneous Angioplasty. Ann Vasc Surg 2014; 28:1005-15. [DOI: 10.1016/j.avsg.2013.11.014] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2013] [Revised: 10/15/2013] [Accepted: 11/09/2013] [Indexed: 10/25/2022]
|
10
|
Laragh JH, Sealey JE. Renin–Angiotensin–Aldosterone System and the Renal Regulation of Sodium, Potassium, and Blood Pressure Homeostasis. Compr Physiol 2011. [DOI: 10.1002/cphy.cp080231] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
11
|
Inhibition of the renin-angiotensin system prevents seizures in a rat model of epilepsy. Clin Sci (Lond) 2010; 119:477-82. [PMID: 20533906 DOI: 10.1042/cs20100053] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
The RAS (renin-angiotensin system) is classically involved in BP (blood pressure) regulation and water-electrolyte balance, and in the central nervous system it has been mostly associated with homoeostatic processes, such as thirst, hormone secretion and thermoregulation. Epilepsies are chronic neurological disorders characterized by recurrent epileptic seizures that affect 1-3% of the world's population, and the most commonly used anticonvulsants are described to be effective in approx. 70% of the population with this neurological alteration. Using a rat model of epilepsy, we found that components of the RAS, namely ACE (angiotensin-converting enzyme) and the AT1 receptor (angiotensin II type 1 receptor) are up-regulated in the brain (2.6- and 8.2-fold respectively) following repetitive seizures. Subsequently, epileptic animals were treated with clinically used doses of enalapril, an ACE inhibitor, and losartan, an AT1 receptor blocker, leading to a significant decrease in seizure severities. These results suggest that centrally acting drugs that target the RAS deserve further investigation as possible anticonvulsant agents and may represent an additional strategy in the management of epileptic patients.
Collapse
|
12
|
Shi L, Mao C, Xu Z, Zhang L. Angiotensin-converting enzymes and drug discovery in cardiovascular diseases. Drug Discov Today 2010; 15:332-41. [PMID: 20170743 PMCID: PMC3005694 DOI: 10.1016/j.drudis.2010.02.003] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2009] [Revised: 12/30/2009] [Accepted: 02/11/2010] [Indexed: 12/24/2022]
Abstract
Angiotensin-converting enzyme (ACE) is a major target in the treatment of cardiovascular diseases (CVDs). In addition to ACE, ACE2 - which is a homolog of ACE and promotes the degradation of angiotensin II (Ang II) to Ang (1-7) - has been recognized recently as a potential therapeutic target in the management of CVDs. This article reviews different metabolic pathways of ACE and ACE2 (Ang I-Ang II-AT1 receptors and Ang I-Ang (1-7)-Mas receptors) in the regulation of cardiovascular function and their potential in new drug development in the therapy of CVDs. In addition, recent progress in the study of angiotensin and ACE in fetal origins of CVD, which might present an interesting field in perinatal medicine and preventive medicine, is briefly summarized.
Collapse
Affiliation(s)
- Lijun Shi
- Department of Human Sport Science, Beijing Sport University, Beijing 100084, China
| | | | | | | |
Collapse
|
13
|
Santos CF, Akashi AE, Dionísio TJ, Sipert CR, Didier DN, Greene AS, Oliveira SHP, Pereira HJV, Becari C, Oliveira EB, Salgado MCO. Characterization of a local renin-angiotensin system in rat gingival tissue. J Periodontol 2009; 80:130-9. [PMID: 19228099 DOI: 10.1902/jop.2009.080264] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
BACKGROUND The systemic renin-angiotensin system (RAS) promotes the plasmatic production of angiotensin (Ang) II, which acts through interaction with specific receptors. There is growing evidence that local systems in various tissues and organs are capable of generating angiotensins independently of circulating RAS. The aims of this study were to investigate the expression and localization of RAS components in rat gingival tissue and evaluate the in vitro production of Ang II and other peptides catalyzed by rat gingival tissue homogenates incubated with different Ang II precursors. METHODS Reverse transcription-polymerase chain reaction assessed mRNA expression. Immunohistochemical analysis aimed to detect and localize renin. A standardized fluorimetric method with tripeptide hippuryl-histidyl-leucine was used to measure tissue angiotensin-converting enzyme (ACE) activity, whereas high performance liquid chromatography showed products formed after the incubation of tissue homogenates with Ang I or tetradecapeptide renin substrate (TDP). RESULTS mRNA for renin, angiotensinogen, ACE, and Ang II receptors (AT(1a), AT(1b), and AT(2)) was detected in gingival tissue; cultured gingival fibroblasts expressed renin, angiotensinogen, and AT(1a) receptor. Renin was present in the vascular endothelium and was intensely expressed in the epithelial basal layer of periodontally affected gingival tissue. ACE activity was detected (4.95 +/- 0.89 nmol histidyl-leucine/g/minute). When Ang I was used as substrate, Ang 1-9 (0.576 +/- 0.128 nmol/mg/minute), Ang II (0.066 +/- 0.008 nmol/mg/minute), and Ang 1-7 (0.111 +/- 0.017 nmol/mg/minute) were formed, whereas these same peptides (0.139 +/- 0.031, 0.206 +/- 0.046, and 0.039 +/- 0.007 nmol/mg/minute, respectively) and Ang I (0.973 +/- 0.139 nmol/mg/minute) were formed when TDP was the substrate. CONCLUSION Local RAS exists in rat gingival tissue and is capable of generating Ang II and other vasoactive peptides in vitro.
Collapse
Affiliation(s)
- C F Santos
- Department of Biological Sciences, Bauru School of Dentistry, University of São Paulo, Bauru, SP, Brazil
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Bourassa EA, Sved AF, Speth RC. Angiotensin modulation of rostral ventrolateral medulla (RVLM) in cardiovascular regulation. Mol Cell Endocrinol 2009; 302:167-75. [PMID: 19027823 PMCID: PMC9686041 DOI: 10.1016/j.mce.2008.10.039] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/12/2008] [Revised: 10/05/2008] [Accepted: 10/24/2008] [Indexed: 02/07/2023]
Abstract
The rostral ventrolateral medulla (RVLM) and the presympathetic bulbospinal neurons in this region play a critical role in cardiovascular regulation. However, there is ambiguity regarding the precise anatomical coordinates of the RVLM and much still needs to be learned regarding the regulation and neurochemistry of this region. This brief review discusses some of these issues and focuses on the role of angiotensin-mediated signaling in the RVLM in blood pressure regulation.
Collapse
Affiliation(s)
- Erick A. Bourassa
- Department of Pharmacology, School of Pharmacy, University of Mississippi, University, MS 38677
- Current address: Biological Sciences, Northwest Missouri State University, Maryville, MO 64468
| | - Alan F. Sved
- Department of Neuroscience and Center for Neuroscience, University of Pittsburgh, Pittsburgh, Pennsylvania 15260
| | - Robert C. Speth
- Department of Pharmacology, School of Pharmacy, University of Mississippi, University, MS 38677
- Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi, University, MS 38677
| |
Collapse
|
15
|
Vamvakas SSM, Leondiadis L, Pairas G, Manessi-Zoupa E, Spyroulias GA, Cordopatis P. Expression, purification, and physicochemical characterization of the N-terminal active site of human angiotensin-I converting enzyme. J Pept Sci 2007; 13:31-6. [PMID: 16972307 DOI: 10.1002/psc.788] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
We have cloned, over expressed, and purified one of the two catalytic domains (residues Ala361 to Gly468, ACE-N) of human somatic angiotensin-I converting enzyme in Escherichia coli. This construct represents the N-catalytic domain including the two binding motifs and the 23 amino acid spacers as well as some amino acid residues before and after the motifs that might help in correct conformation. The overexpressed protein was exclusively localized to insoluble inclusion bodies. Inclusion bodies were solubilized in an 8-M urea buffer. Purification was carried out by differential centrifugation and gel filtration chromatography under denaturing conditions. About 12 mg of ACE-N peptide per liter of bacterial culture was obtained. The integrity of recombinant protein domain was confirmed by ESI/MS. Structural analysis using CD spectroscopy has shown that, in the presence of TFE, the ACE-N protein fragment has taken a conformation, which is consistent with the one found in testis ACE by X-ray crystallography. This purification procedure enables the production of an isotopically labeled protein fragment for structural studying in solution by NMR spectroscopy.
Collapse
Affiliation(s)
- Sotirios-Spyridon M Vamvakas
- Laboratory of Mass Spectrometry and Dioxin Analysis, National Center for Scientific Research Demokritos, 27 Neapoleos Str, GR-15310 Athens, Greece
| | | | | | | | | | | |
Collapse
|
16
|
Patchett AA, Cordes EH. The design and properties of N-carboxyalkyldipeptide inhibitors of angiotensin-converting enzyme. ADVANCES IN ENZYMOLOGY AND RELATED AREAS OF MOLECULAR BIOLOGY 2006; 57:1-84. [PMID: 2994404 DOI: 10.1002/9780470123034.ch1] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Angiotensin-converting enzyme inhibitors promise to make important therapeutic contributions to the control of hypertension and congestive heart failure. The nonapeptide teprotide was the first of these inhibitors to be tested clinically. It was followed by orally active inhibitors, captopril in 1977 and enalapril in 1980. The latter is representative of a new design for the inhibition of metallopeptidases and is the subject of this review. The best of the N-carboxyalkyldipeptide inhibitors inhibits angiotensin-converting enzyme with a Ki of 7.6 X 10(-11) M. This compound is the most potent competitive inhibitor of a metallopeptidase yet to have been reported. The basis of this high potency is beginning to be understood and in part is considered to involve precisely arranged multiple interactions within the enzyme active site. X-ray crystallography of a thermolysin-inhibitor complex has been achieved. Assuming that similar interactions within the active site of angiotensin-converting enzyme are mechanistically probable, the authors hypothesize the binding of enalaprilat to converting enzyme as shown in Figure 24. Such interactions are consistent with kinetic studies (Section V) with the understanding that binding to the enzyme is not sensitive to the inhibitor's state of NH protonation. The reason for this surprising conclusion has not been established. Perhaps counterbalancing factors are involved in the energetics of binding or there may be compensating adjustments made in the enzyme which permit NH protonated and nonprotonated inhibitor to bind equally well. Figure 24 also summarizes present understanding of the conformation of enalaprilat when bound to angiotensin-converting enzyme. From studies on conformationally defined analogs of enalaprilat, it seems likely that the Ala-Pro segment of enalaprilat binds in a conformation that is close to a minimum energy conformer. This situation no doubt contributes to the potency of enalaprilat, since little binding energy would be needed to induce conformational changes in this part-structure of enalaprilat when it is bound to the enzyme. The phenethyl group of enalaprilat is believed to be near the alpha-hydrogen of the L-Ala residue in the enzyme-inhibitor complex. However, the synthesis of conformationally restricted analogs to establish this point has not yet been reached. The N-carboxyalkylpeptide design was developed from Wolfenden's collected product inhibitors of carboxypeptidase-A. Whether or not N-carboxyalkyldipeptides should be classified as collected product or transition state inhibitors is unclear.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
|
17
|
Fitzsimons JT. Angiotensin stimulation of the central nervous system. Rev Physiol Biochem Pharmacol 2005; 87:117-67. [PMID: 6252591 DOI: 10.1007/bfb0030897] [Citation(s) in RCA: 146] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
18
|
Santos CF, Greene AS, Salgado MCO, Oliveira EB. Conversion of renin substrate tetradecapeptide to angiotensin II by rat MAB elastase-2. Can J Physiol Pharmacol 2004; 82:1000-5. [PMID: 15644940 DOI: 10.1139/y04-102] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
A new approach for the purification of rat mesenteric arterial bed (MAB) elastase-2 has been developed using the chromogenic substrates N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide and N-succinyl-Ala-Ala-Pro-Leu-p-nitroanilide to monitor the enzymatic activity during various stages of purification. The purified enzyme was evaluated in the presence of various inhibitors and confirmed to have angiotensin (Ang) II-forming ability. The active site-directed inhibitor acetyl-Ala-Ala-Pro-Leu-chloromethylketone (100 µmol·L-1), described for human pancreatic elastase-2, abolished the enzymatic activity, confirming that the enzyme is an elastase-2. Chymostatin (100 µmol·L-1), an inhibitor regarded as selective for chymases, also showed a remarkable inhibitory effect (94%), whereas captopril (100 µmol·L-1) had no effect at all on the Ang II-forming activity. The Ang II precursor renin substrate tetradecapeptide (RS-14P) was converted into Ang II by the rat MAB elastase-2 with the following kinetic constants: Km= 124 ± 21 µmol·L-1; Kcat= 629 min-1; catalytic efficiency (Kcat/Km) = 5.1 min-1µ(mol/L)-1. In conclusion, the strategy for the purification of rat MAB elastase-2 with the chromogenic substrates proved to be simple, rapid, accurate, and highly reproducible; therefore, it can be reliably and conveniently used to routinely purify this enzyme. The kinetic parameters for the formation of Ang II from RS-14P by rat MAB elastase-2 emphasize differences in substrate specificity between this and other Ang II-forming enzymes.Key words: N-succinyl-Ala-Ala-Pro-Phe-p-nitroanilide, N-succinyl-Ala-Ala-Pro-Leu-p-nitroanilide, elastase-2, angiotensin II, renin substrate tetradecapeptide.
Collapse
Affiliation(s)
- Carlos F Santos
- Discipline of Pharmacology, Bauru School of Dentistry, University of São Paulo, Brazil
| | | | | | | |
Collapse
|
19
|
Buss S, Müller-Thomsen T, Hock C, Alberici A, Binetti G, Nitsch RM, Gal A, Finckh U. No association between DCP1 genotype and late-onset Alzheimer disease. AMERICAN JOURNAL OF MEDICAL GENETICS 2002; 114:440-5. [PMID: 11992568 DOI: 10.1002/ajmg.10306] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
In a study of 261 patients with Alzheimer disease (AD) and 306 cognitively normal control subjects from Germany, Switzerland, and Italy, we found no association between genotype counts or allelic frequencies of DCP1, the gene encoding angiotensin-converting enzyme. In accordance with several other studies, our data could not confirm previous association findings. Critical review about all studies available on DCP1 genotyping and AD, age-associated cognitive decline, longevity, and other conditions revealed remarkable inconsistencies. Several studies showed significant deviations of genotype counts from Hardy Weinberg equilibrium (HWE). Deviations from HWE may limit the comparability of study results and require clarification before drawing conclusions with respect to disease risk, health conditions, or longevity in association with DCP1 genotype.
Collapse
Affiliation(s)
- Svenja Buss
- Department of Human Genetics, University Hospital Hamburg-Eppendorf, University of Hamburg, Hamburg, Germany
| | | | | | | | | | | | | | | |
Collapse
|
20
|
Binkley PF, Nunziata E, Haas GJ, Starling RC, Leier CV, Cody RJ. Dissociation between ACE activity and autonomic response to ACE inhibition in patients with heart failure. Am Heart J 2000; 140:34-42. [PMID: 10874261 DOI: 10.1067/mhj.2000.107180] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
BACKGROUND Administration of angiotensin-converting enzyme (ACE) inhibitors to patients with congestive heart failure has been shown to increase parasympathetic tone as indicated by increases in high-frequency heart rate variability. The mechanism for this effect, including its relation to changes in baroreflex activity, blood pressure variability, and suppression of ACE activity, remains undefined. This study was designed to test the relation of these variables, which may govern changes in autonomic activity, to the previously described increase in parasympathetic tone. METHODS Seven patients with heart failure received a 3-hour infusion of the ACE inhibitor enalaprilat. Hemodynamic variables and parameters of heart rate and blood pressure variability, baroreflex gain derived from the interaction of heart rate and blood pressure variability, and serum ACE activity were measured during and after the infusion. Measures of heart rate and blood pressure variability were also compared against a historic control group. RESULTS Serum ACE activity was significantly suppressed throughout and after enalaprilat infusion. Hemodynamic measures did not change other than a small decline in right atrial and pulmonary capillary wedge pressures. Parasympathetic tone showed an initial significant increase with a peak at 2 hours but then declined below baseline 8 hours after initiation of enalaprilat infusion. Sympathetically influenced low-frequency heart rate variability was significantly increased above baseline in the enalaprilat treatment group 8 hours after initiation of the infusion. Baroreflex gain showed a significant trend to an increase with the maximum value coinciding with the peak in parasympathetic tone. There was no change in blood pressure variability in the enalaprilat group and no change in baroreflex gain, heart rate variability, or blood pressure variability in the control group. CONCLUSIONS Parasympathetic tone and baroreflex gain increased with parenteral administration of an ACE inhibitor but subsequently decreased below baseline values despite continued suppression of serum ACE activity. The dissociation between ACE suppression and autonomic response to ACE inhibition indicates that enzyme systems not reflected by plasma ACE activity or independent from the classic pathways of angiotensin formation contribute to the regulation of the autonomic response to ACE inhibition in patients with heart failure. The absence of significant change in hemodynamic variables or in blood pressure variability indicates that these autonomic changes are not an indirect reflex response to ACE inhibitor-induced vasodilation or hemodynamic baroreceptor stimulation.
Collapse
|
21
|
Chapter VII Brain kallikrein–kinin system: from receptors to neuronal pathways and physiological functions. HANDBOOK OF CHEMICAL NEUROANATOMY 2000. [DOI: 10.1016/s0924-8196(00)80009-3] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
22
|
Paula CA, Sousa MV, Salgado MC, Oliveira EB. Purification and substrate specificity of an angiotensin converting elastase-2 from the rat mesenteric arterial bed perfusate. BIOCHIMICA ET BIOPHYSICA ACTA 1998; 1388:227-38. [PMID: 9774738 DOI: 10.1016/s0167-4838(98)00186-1] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
Abstract
A soluble angiotensin (Ang) II-generating enzyme has been purified to homogeneity from the rat mesenteric arterial bed (MAB) perfusate by a combination of gel filtration and affinity chromatographies. The enzyme is a glycoprotein of 28.5 kDa (SDS-PAGE), whose N-terminal sequence is identical with that of the rat pancreatic elastase-2; therefore the enzyme will henceforth be referred to as rat MAB elastase-2. When Ang I was used as the substrate, the enzyme specifically released Ang II and the dipeptide His-Leu (Km=36 microM; Kcat=1530 min-1). The catalytic efficiency (Kcat/Km=42.5 min-1 microM-1) of this reaction was comparable to those of other known Ang I-converting enzymes. The proteolytic specificity of the purified enzyme toward mellitin, oxidized insulin B chain, somatostatin-14 and renin substrate tetradecapeptide suggested that the enzyme-substrate interaction was defined by an extended substrate binding site, typical of elastases-2 of pancreatic origin. According to the sensitivity of the rat MAB elastase-2 to various inhibitors this enzyme could be described as a member of the chymostatin-sensitive group of Ang II-forming serine proteases. The localization and biochemical properties of this enzyme suggest that it might play a role in the regional control of vascular tonus.
Collapse
Affiliation(s)
- C A Paula
- Department of Biochemistry, Faculty of Medicine, University of São Paulo, 14049-900 Ribeirão Preto, SP, Brazil
| | | | | | | |
Collapse
|
23
|
Moody TW, Mayr CA, Gillespie TJ, Davis TP. Neurotensin is metabolized by endogenous proteases in prostate cancer cell lines. Peptides 1998; 19:253-8. [PMID: 9493857 DOI: 10.1016/s0196-9781(97)00306-9] [Citation(s) in RCA: 21] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The formation and processing of neurotensin (NT) by three prostate cancer cell lines was investigated. Neurotensin (NT) immunoreactivity was detected in conditioned media and extracts of LNCaP cells. Using HPLC techniques, the immunoreactivity extracted from LNCaP cells coeluted with synthetic NT standard. Metalloendopeptidase 3.4.24.15 activity was detected in PC-3, DU-145 and LNCaP cells, whereas high levels of neutral endopeptidase 3.4.24.1 1 activity was detected only in LNCaP cells. NT was relatively stable when incubated with PC-3 or D-145 cells but was rapidly degraded by LNCaP cells to NT1-11 and NT1-10. Phosphoramidon inhibited the metabolism of NT by LNCaP cells. These data suggest that NT is present in and metabolized by LNCaP cellular enzymes.
Collapse
Affiliation(s)
- T W Moody
- Biomarkers and Prevention Research Branch, National Cancer Institute, Rockville, MD 20850, USA
| | | | | | | |
Collapse
|
24
|
Paul M, Stoll M, Kreutz R, Fernandez-Alfonso MS. The cellular basis of angiotensin converting enzyme mRNA expression in rat heart. Basic Res Cardiol 1996; 91 Suppl 2:57-63. [PMID: 8957546 DOI: 10.1007/bf00795364] [Citation(s) in RCA: 57] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Angiotensin converting enzyme (ACE) is a key factor in the regulation of two peptide systems: the renin angiotensin system (RAS) and the kinin-kallikrein system (KKS). Since it is involved in the biosynthesis of Angiotensin II (Ang II) as well as in the degradation of bradykinin (BK) it could play an important role in cardiovascular physiology and pathophysiology. ACE is widely expressed in the heart and upregulated in pathophysiological situations such as heart failure and cardiac hypertrophy. In addition, inhibition of ACE has beneficial effects in these conditions. Whereas the regulation of cardiac ACE has been studied extensively, little is known concerning the cellular expression of ACE in cardiac tissue. To define the cellular localization of ACE mRNA expression in the rat heart, we separated coronary microvascular endothelial cells from cardiac myocytes using differential centrifugation and growth on selective media. ACE mRNA expression was measured by a specific polymerase chain reaction assay after reverse transcription (RT-PCR) in different cardiac cells. The studies showed that ACE is differentially expressed in endothelial cells as well as in cardiac myocytes. This differential regulation of ACE in myocytes and non-myocytes may play a role for the diverse actions of the cardiac angiotensin system under physiological and pathological conditions.
Collapse
Affiliation(s)
- M Paul
- University Hospital Benjamin Franklin, Institute for Clinical Pharmacology, Berlin, Germany
| | | | | | | |
Collapse
|
25
|
Khan IM, Miller DH, Strickland J, Margolius HS, Privitera PJ. Brain kallikrein-kinin system abnormalities in spontaneously hypertensive rats. Hypertension 1995; 25:524-30. [PMID: 7721393 DOI: 10.1161/01.hyp.25.4.524] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The objective of the present study was to determine whether the brain kallikrein-kinin system differs between spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto rats (WKY) and if so, whether any detected differences occur before the development of hypertension in SHR. We measured cerebrospinal fluid levels of various components of the system in adult and young prehypertensive SHR and WKY. Cerebrospinal fluid kinin concentration and appearance rate were higher in SHR. Cerebrospinal fluid active kallikrein level and kininogenase activity were also higher in adult SHR. In addition, cerebrospinal fluid kinin concentration and appearance rate were higher in prehypertensive, 5- to 6-week-old SHR compared with age-matched WKY. However, no differences in cerebrospinal fluid kallikrein or kininogenase activity were observed between the two strains of young rats. Cerebrospinal fluid kinin concentration was higher in young versus adult rats of the same strain. In WKY, cerebrospinal fluid kallikrein also decreased with age although cerebrospinal fluid kallikrein concentration did not decrease in young and adult SHR. Together, these data suggest that there is a hyperactive kallikrein-kinin system in the brain of SHR that may contribute to the hypertensive state in this animal model.
Collapse
Affiliation(s)
- I M Khan
- Department of Pharmacology, Medical University of South Carolina, Charleston 29425, USA
| | | | | | | | | |
Collapse
|
26
|
Weekley LB. Tissue and plasma peptidase activity is altered during hypothermic hibernation in the 13 lined ground squirrel (Spermophilus tridecemlineatus). Physiol Behav 1995; 57:595-8. [PMID: 7753901 DOI: 10.1016/0031-9384(94)00304-n] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Adult 13 lined ground squirrels were monitored for entry into a state of hypothermic hibernation or arousal in a cold room on a photoperiod LD 2:22. Once animals developed predictable hibernation patterns, animals were killed at the mid point of hypothermic hibernation or arousal for determination of plasma and tissue angiotensin-1-converting enzyme (Kininase II) activity. Enzyme was extracted from plasma, lung, kidney, liver, forebrain and brainstem and assayed in vitro. During hypothermic hibernation enzyme activity is significantly decreased in all tissues examined. These data suggest that the activity of tissue and plasma peptidases are altered during the cyclic torporous periods characteristics of hibernation in this species.
Collapse
Affiliation(s)
- L B Weekley
- Department of Zoology and Physiology, University of Wyoming, Laramie 82071, USA
| |
Collapse
|
27
|
Brice EA, Friedlander W, Bateman ED, Kirsch RE. Serum angiotensin-converting enzyme activity, concentration, and specific activity in granulomatous interstitial lung disease, tuberculosis, and COPD. Chest 1995; 107:706-10. [PMID: 7874941 DOI: 10.1378/chest.107.3.706] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
Angiotensin-converting enzyme (ACE) activity in serum is used as an aid to the diagnosis and follow-up of patients with sarcoidosis. A theoretical limitation of measurements of activity is that these may be affected by the presence of pharmacologic or endogenous inhibitors of ACE. Immunoassays of ACE concentration avoid this problem and, when combined with tests of ACE activity, permit calculation of specific activity of ACE. In this study, we set out to develop a sensitive radioimmunoassay for ACE to compare results obtained with this method with results of ACE activity and calculated ACE specific activity in patients suffering from a variety of lung diseases. In a group of control subjects (n = 32), the ACE concentration was 453.7 +/- 159.8 (SD) ng/mL; 95% confidence interval (CI), 398.34 to 509.06, but levels were significantly elevated in sarcoidosis (979.3 +/- 558.6 ng/mL; 95% CI, 827.5 to 1,131.1; n = 51; p < 0.001 vs control subjects), silicosis (646.5 +/- 239.1 ng/mL; 95% CI, 544.2 to 748.8; n = 21; p < 0.01), and miliary tuberculosis (647.0 +/- 217.1 ng/mL; 95% CI, 551.9 to 742.1; n = 29; p < 0.01). The levels were normal in COPD, interstitial pulmonary fibrosis, and active cavitary pulmonary tuberculosis. The overall correlation between ACE activity and concentration measurements was strong (r = 0.93). No evidence of endogenous ACE inhibition was observed in any of the disease categories studied except in COPD where an elevation of ACE specific activity was observed, raising the possibility that in this condition different isozymes of ACE with higher specific activity might be released.
Collapse
Affiliation(s)
- E A Brice
- MRC/UCT Liver Research Centre, University of Cape Town, Republic of South Africa
| | | | | | | |
Collapse
|
28
|
[22] Autoradiographic techniques to map angiotensin-converting enzyme in brain and other tissues. ACTA ACUST UNITED AC 1995. [DOI: 10.1016/s1043-9471(06)80133-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register]
|
29
|
Lippoldt A, Paul M, Fuxe K, Ganten D. The brain renin-angiotensin system: molecular mechanisms of cell to cell interactions. Clin Exp Hypertens 1995; 17:251-66. [PMID: 7735273 DOI: 10.3109/10641969509087069] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The components of the Renin-Angiotensin System (RAS) have been found to be expressed in the brain. Angiotensinogen, the high molecular weight precursor of the system, is widely distributed and expressed in areas not related to control of blood pressure and body fluid homeostasis as well. It has been shown that it is regulated by steroid hormones independently from the liver and that it is also regulated in a different manner in several brain areas. Angiotensin II, the effector peptide of the system, may be generated in the brain via the classical pathway, using renin and angiotensin converting enzyme or directly from angiotensinogen by cathepsin G or tonin. N-terminal peptides of angiotensin II have been found in several brain areas with ANG (1-7) involved in vasopressin release however without influence on blood pressure and with ANG III acting as potent as ANG II. Transgenic animals may be used to study the pathophysiology of an activated brain RAS.
Collapse
Affiliation(s)
- A Lippoldt
- Max-Delbrück-Center for Molecular Medicine (MDC) Berlin-Buch, FRG
| | | | | | | |
Collapse
|
30
|
Wu JN, Berecek KH. Prevention of genetic hypertension by early treatment of spontaneously hypertensive rats with the angiotensin converting enzyme inhibitor captopril. Hypertension 1993; 22:139-46. [PMID: 8340149 DOI: 10.1161/01.hyp.22.2.139] [Citation(s) in RCA: 117] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Our purpose was to evaluate whether early treatment of spontaneously hypertensive rats (SHR) with the angiotensin converting enzyme inhibitor captopril could permanently alter the course of hypertension. Mating pairs of SHR were treated with captopril, and their pups were maintained on captopril until experimentation. Some captopril-treated rats were taken off treatment at 2 months of age, and then some of these rats were mated at 3 months of age. The mean arterial pressures of conscious captopril-treated rats, the rats removed from therapy, and the offspring of the rats removed from therapy were significantly smaller than control rats at 4 and 9 months of age. Central administration of angiotensin I or II induced significantly smaller increases in blood pressure and drinking in captopril-treated rats and the rats removed from therapy compared with control rats. The increase in blood pressure in response to intravenous injection of angiotensin I or II was similar among all groups, with the exception that captopril-treated rats showed lesser pressor responses to angiotensin I. Early administration of captopril, even after administration was stopped, prevented the subsequent development of hypertension in SHR and altered the course of development of hypertension in their progeny. This effect was associated with decreased central responses to angiotensin I and II. Our data suggest that captopril may permanently alter the development of hypertension in SHR through an alteration in the central renin-angiotensin system.
Collapse
Affiliation(s)
- J N Wu
- Department of Physiology and Biophysics, University of Alabama, Birmingham 35294
| | | |
Collapse
|
31
|
Dauch P, Masuo Y, Vincent JP, Checler F. A survey of the cerebral regionalization and ontogeny of eight exo- and endopeptidases in murines. Peptides 1993; 14:593-9. [PMID: 8332554 DOI: 10.1016/0196-9781(93)90150-f] [Citation(s) in RCA: 28] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
We have established the cerebral regionalization and ontogeny of eight exo- and endopeptidases in murines. Aminopeptidases A, B, and M, post-proline dipeptidylaminopeptidase (DAP IV), and proline endopeptidase displayed a rather homogenous distribution within the brain regions with a three- to fourfold factor between the poorest and richest areas. Aminopeptidases M and B appeared maximal in the parietal cortex and nucleus accumbens, respectively, while proline endopeptidase was abundant in the piriform cortex. By contrast with the peptidases exhibiting a rather homogenous distribution, endopeptidase 24.11, angiotensin-converting enzyme, and, to a lesser extent, endopeptidase 24.15 appeared located in much more discrete cerebral zones. Angiotensin-converting enzyme activity was mainly restricted to the nigro-striatal axis. Such feature also stands for endopeptidase 24.11, which was also detected in additional zones corresponding to the globus pallidus and the nucleus accumbens. Endopeptidase 24.15 activity was maximal in the nucleus accumbens and particularly weak in the mamillary body. Neuropeptidases appeared differently regulated during development of mouse brain. Aminopeptidase M, DAP IV, and endopeptidase 24.15 were detected in utero, and their specific activities did not significantly vary until adulthood. Proline endopeptidase and endopeptidase 24.11 were detected in high quantity at day 9 before birth, then activity decreased until birth. Then, proline endopeptidase augmented and plateaued between day 3 and day 10, while endopeptidase 24.11 remained constant at a relatively low level. Finally, angiotensin-converting enzyme was virtually undetectable at early stages before parturition, then slightly increased after birth. The possibility that distinct cerebral regionalization and ontogeny of peptides could directly influence peptide physiology and/or reflect additional functions of the peptidases besides peptide degradation is discussed.
Collapse
Affiliation(s)
- P Dauch
- Institut de Pharmacologie Moléculaire et Cellulaire, CNRS UPR 411, Université de Nice, Valbonne, France
| | | | | | | |
Collapse
|
32
|
Matucci-Cerinic M, Lombardi A, Leoncini G, Pignone A, Sacerdoti L, Spillantini MG, Partsch G. Neutral endopeptidase (3.4.24.11) in plasma and synovial fluid of patients with rheumatoid arthritis. A marker of disease activity or a regulator of pain and inflammation? Rheumatol Int 1993; 13:1-4. [PMID: 8390712 DOI: 10.1007/bf00290326] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
In recent years the role of the peripheral nervous system has been focused on the pathogenesis of rheumatoid arthritis (RA). In particular, substance P (SP), released by the sensory terminals, has been demonstrated to be involved in cartilage breakdown [13]. The aim of our work was to study the levels of SP and its peptidases, neutral endopeptidase (3.4.24.11) (NEP) and angiotensin-converting enzyme (ACE), in the synovial fluid and plasma of 30 patients with RA and 14 patients with osteoarthritis (OA). ACE and NEP were determined with a fluorimetric assay and SP with a radioimmunoassay (RIA) method. ACE levels were normal in the plasma of patients with RA and OA (6.1 +/- 1.9 and 6.7 +/- 1.4 pmol/ml/min, respectively); we found no differences in the values, of ACE between RA and OA synovial fluid (5.7 +/- 4.2 and 5.5 +/- 4.1 pmol/ml/min, respectively). NEP levels were significantly increased in plasma (139.3 +/- 36 pmol/ml/min) and synovial fluid (133.8 +/- 32 pmol/ml/min) of patients with RA when compared to patients with OA (73.4 +/- 22 in plasma and 15.2 +/- 10.8 pmol/ml/min in synovial fluid) and healthy controls (89.7 +/- 14 pmol/ml/min in plasma). In synovial fluid, SP was significantly higher in RA patients (43.1 +/- 16.6 pg/ml) than in OA patients (12 +/- 13.1 pg/ml), while plasma levels did not show any difference (RA: 14.4 +/- 10.2; OA: 13.6 +/- 10.6; healthy subjects: 11.3 +/- 3.9 pg/ml). The only relationship detected in controls and in OA was among plasma NEP and ESR (P < 0.05) and synovial fluid NEP (P < 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
|
33
|
Meng QC, King SJ, Branham KE, Delucas LJ, Lorber B, Oparil S. Preparative isolation of angiotensin-converting enzyme from human lung. JOURNAL OF CHROMATOGRAPHY 1992; 579:63-71. [PMID: 1332983 DOI: 10.1016/0378-4347(92)80363-u] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Angiotensin-converting enzyme from human lung was purified to apparent homogeneity using a five-step purification procedure consisting of ammonium sulfate precipitation, ion-exchange chromatography on DEAE Sephadex A-50, gel permeation on Sephadex G-200, chromatofocusing on a polybuffer exchange (PBE 94) column and high-performance liquid chromatographic gel permeation on a Bio-Sil TSK-250 column. This procedure gave an approximately 700-fold purification with a 20% yield compared to a 550-fold purification and a 1% yield with an affinity chromatography-based procedure. The 20-fold greater yield of the five-step procedure offers a major advantage for preparative use in the structural characterization of angiotensin-converting enzyme.
Collapse
Affiliation(s)
- Q C Meng
- Department of Cell Biology and Medicine, University of Alabama, Birmingham 35294
| | | | | | | | | | | |
Collapse
|
34
|
Hayakawa M. Platelet angiotensin II in cerebrovascular accident and the effect of angiotensin-converting enzyme inhibitors. J Int Med Res 1992; 20:289-94. [PMID: 1397674 DOI: 10.1177/030006059202000311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Platelet angiotensin II concentrations were significantly (P less than 0.01) elevated in 16 patients with a history of cerebral infarction, compared with 12 control subjects. The angiotensin-converting enzyme inhibitors, captopril, enalapril and delapril hydrochloride, were evaluated in 20 hypertensive patients with a history of cerebral infarction. Each agent was administered orally each day for 12 weeks using an open randomized crossover design. After 4 weeks' treatment, 75 mg/kg captopril significantly (P less than 0.01) increased platelet angiotensin II concentrations and the increase was maintained for a further 8 weeks. Treatment with 5 mg/day enalapril resulted in no significant change in angiotensin II. Treatment with 30 mg/day delapril hydrochloride significantly (P less than 0.05) decreased platelet angiotensin II concentrations at 4 weeks and the change persisted for 12 weeks (P less than 0.01). During delapril hydrochloride treatment platelet angiotensin II concentrations approached normal values. It is concluded that delapril hydrochloride may be used to treat patients with arteriosclerosis disorders and may inhibit the tendency for atherosclerotic changes and thrombosis.
Collapse
Affiliation(s)
- M Hayakawa
- Department of Geriatrics, Nagoya University School of Medicine, Japan
| |
Collapse
|
35
|
Song K, Allen AM, Paxinos G, Mendelsohn FA. Mapping of angiotensin II receptor subtype heterogeneity in rat brain. J Comp Neurol 1992; 316:467-84. [PMID: 1577995 DOI: 10.1002/cne.903160407] [Citation(s) in RCA: 246] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Angiotensin II (Ang II) exerts a number of central actions on fluid and electrolyte homeostasis, autonomic activity, and neuroendocrine regulation. In order to evaluate likely sites where these actions are mediated, Ang II receptor binding was localized in rat brain by in vitro autoradiography with the aid of the antagonist analogue 125I-[Sar1, Ile8]Ang II. Two subtypes of Ang II receptor have been identified using recently developed peptide and nonpeptide antagonists. In the periphery, the receptor subtypes differ in distribution, second messenger coupling, and function. Brain Ang II receptor subtypes were therefore differentiated into AT-1 (type I) and AT-2 (type II) subtypes by using unlabelled nonpeptide antagonists specific for the two Ang II subtypes. AT-1 binding was determined to be that inhibited by Dup 753 (10 microM) and AT-2 binding to be that inhibited by PD 123177 (10 microM). The reducing agent dithiothreitol (DTT) decreased binding to AT-1 receptors and enhanced binding to AT-2 receptors. Many brain structures, such as the vascular organ of the lamina terminalis, subfornical organ, median preoptic nucleus, area postrema, nucleus of the solitary tract, and dorsal motor nucleus of the vagus, which are known to be related to the central actions of Ang II, contain exclusively AT-1 Ang II receptors. By contrast, the locus coeruleus, ventral and dorsal parts of lateral septum, superior colliculus and subthalamic nucleus, many nuclei of the thalamus, and nuclei of the inferior olive contain predominantly AT-2 Ang II receptors. The detailed binding characteristics of each subtype were determined by competition studies with a series of analogues of angiotensin and antagonists. The pharmacological specificity obtained in rat superior colliculus and the nucleus of the solitary tract agreed well with published data on AT-1 and AT-2 receptors, respectively. There was a high degree of correlation between the distribution of Ang II binding sites with published data on Ang II-immunoreactive fields and on the sites of Ang II-responsive neurons. The present study also reveals pharmacological heterogeneity of brain Ang II receptors. The subtype-specific receptor mapping described here is relevant to understanding the role of angiotensin peptides in the central nervous system and newly discovered central actions of nonpeptide Ang II receptor antagonists.
Collapse
Affiliation(s)
- K Song
- Department of Medicine, Austin Hospital, University of Melbourne, Heidelberg, Victoria, Australia
| | | | | | | |
Collapse
|
36
|
Abstract
Regional differences in neurotensin metabolism and the peptidases involved were studied using intact, viable rat brain microslices and specific peptidase inhibitors. Regional brain slices (2 mm x 230 microns) prepared from nucleus accumbens, caudate-putamen, and hippocampus were incubated for 2 h in the absence and presence of phosphoramidon, captopril, N-[1(R,S)-carboxy-3-phenylpropyl]-Ala-Ala-Phe-p-aminobenzoate, and o-Phenanthroline, which are inhibitors of neutral endopeptidase 24.11, angiotensin-converting enzyme, metalloendopeptidase 24.15, and nonspecific metallopeptidases, respectively. Neurotensin-degrading proteolytic activity varied by brain region. Significantly less (35.0 +/- 1.6%) neurotensin was lost from hippocampus than from caudate-putamen (45.4 +/- 1.0%) or nucleus accumbens (47.8 +/- 1.1%) in the absence of inhibitors. Peptidases responsible for neurotensin metabolism on brain slices were found to be predominantly metallopeptidases. Metalloendopeptidase 24.15 is of major importance in neurotensin metabolism in each brain region studied. The relative contribution of specific peptidases to neurotensin metabolism also varied by brain region; angiotensin-converting enzyme and neutral endopeptidase 24.11 activities were markedly elevated in the caudate-putamen as compared with the nucleus accumbens or hippocampus. Interregional variation in the activity of specific peptidases leads to altered neurotensin fragment formation. The brain microslice technique makes feasible regional peptide metabolism studies in the CNS, which are impractical with synaptosomes, and provides evidence for regional specificity of neurotensin degradation.
Collapse
Affiliation(s)
- T P Davis
- Department of Pharmacology, College of Medicine, University of Arizona, Tucson 85724
| | | | | |
Collapse
|
37
|
Weiner MF, Bonte FJ, Tintner R, Ford N, Svetlik D, Riall T. ACE inhibitor lacks acute effect on cognition or brain blood flow in alzheimer's disease. Drug Dev Res 1992. [DOI: 10.1002/ddr.430260410] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
38
|
Oliveira EB, Salgado MC, Turner AJ. A survey of vasoactive peptide metabolizing enzymes in the rat mesenteric arterial bed perfusate. Biochem Pharmacol 1991; 42:1897-904. [PMID: 1741767 DOI: 10.1016/0006-2952(91)90587-u] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
We have demonstrated that the isolated perfused rat mesenteric arterial bed (MAB) secretes peptidases capable of metabolizing bradykinin and angiotensin I. The major degradative pathway of bradykinin by enzymes found in the rat MAB perfusate was mediated by carboxypeptidase A-like activity, whereas angiotensin 1 degradation followed two main routes, one attributable to a carboxypeptidase A-like enzyme and the other to an endopeptidase. This latter enzyme seems to be a novel serine peptidase capable of releasing angiotensin II directly from both angiotensin I and renin substrate tetradecapeptide. The rat MAB perfusate was also shown to contain additional endo- and exopeptidases that might play a role in the metabolism of other vasoactive peptides. Our finding that isolated rat MAB secretes peptidases into the perfusion medium indicates that peptide processing within the microvasculature environment may be effected by enzymes besides those normally found in plasma or associated with cell membranes.
Collapse
Affiliation(s)
- E B Oliveira
- Department of Biochemistry, Faculty of Medicine, University of São Paulo, Ribeirão Preto, Brazil
| | | | | |
Collapse
|
39
|
Grekhova TV, Komissarova NV, Romanova GA. Changes in angiotensin converting enzyme activity in rat brain structures after frontal lobectomy. Bull Exp Biol Med 1991. [DOI: 10.1007/bf00840592] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
40
|
Barnes NM, Costall B, Egli P, Horovitz ZP, Ironside JW, Naylor RJ, Williams TJ. Characterisation of [3H]ceranapril recognition sites in rat and human brain tissue. Neuropharmacology 1991; 30:907-14. [PMID: 1664073 DOI: 10.1016/0028-3908(91)90126-v] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The present studies assessed the nature of the recognition site for [3H]ceranapril in tissue from rat and human brain. [3H]Ceranapril exhibited high affinity saturable specific (defined by 1 microM captopril) binding to homogenates of tissue from both rat and human brain (mean pKd values between 8.42 and 8.69). High binding densities were observed in rat striatum and homogenates of tissue from human caudate (Bmax values 3317 +/- 192 and 1900 +/- 110 fmol/mg protein respectively), with comparatively low densities in cortical tissues. In kinetic experiments, association of [3H]ceranapril to homogenates of rat and human cortex was found to be rapid and fully reversible (K+1 = 6 x 10(5) M-1 sec-1 and 2.4 x 10(6) M-1 sec-1, K-1 = 7.6 x 10(-3) sec-1 and 4.5 x 10(-3) sec-1 respectively). In competition studies, lisinopril, captopril, unlabelled ceranapril, epicaptopril and fosinopril, all competed to a similar extent and with similar rank order of potency for the binding of [3H]ceranapril to homogenates of both rat and human brain. In in vivo studies, pretreatment of rats with either captopril or lisinopril (15 micrograms/250 g) significantly reduced the content of tritium in brain, as measured 20 min after intravenous administration of [3H]ceranapril. From these experiments [3H]ceranpril appears to selectively label, with high affinity, the inhibitor binding site of angiotensin converting enzyme and this site appears to be similar in both species studied.
Collapse
Affiliation(s)
- N M Barnes
- Postgraduate Studies in Pharmacology, School of Pharmacy, University of Bradford, West Yorkshire, U.K
| | | | | | | | | | | | | |
Collapse
|
41
|
Checler F, Dauch P, Masuo Y, Vincent JP. Neurotensin and neuromedin N are differently metabolized in ventral tegmental area and nucleus accumbens. J Neurochem 1991; 56:1320-8. [PMID: 2002345 DOI: 10.1111/j.1471-4159.1991.tb11428.x] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Whole homogenates and membrane-bound and cytosoluble fractions prepared from rat ventral tegmental area (VTA) and nucleus accumbens were examined for their content of peptidasic activities and for their ability to metabolize neurotensin and its natural related hexapeptide neuromedin N. No qualitative differences were observed between these two brain regions concerning the presence and the subcellular distribution of a series of activities able to hydrolyze various specific fluorimetric enzymatic substrates. However, aminopeptidase B, endopeptidase 24-15, and endopeptidase 24-11 were significantly lower in the VTA than in the nucleus accumbens membrane preparations, while proline endopeptidase was detected in significantly higher amount only in the cytosolic fraction prepared from nucleus accumbens. Both neurotensin and neuromedin N were metabolized more rapidly in the nucleus accumbens than in the VTA. Furthermore, the degradation rate of neuromedin N was considerably faster than that of neurotensin whatever the cerebral area examined. Studies carried out with highly specific peptidase inhibitors revealed that endopeptidase 24-15 mainly contributed to the catabolism of neurotensin in homogenates and membrane-bound preparations of nucleus accumbens and VTA, while aminopeptidase B appeared predominantly responsible for the rapid disappearance of neuromedin N in both cerebral tissues. The possibility that the different metabolic processes of the two peptide congeners could explain their distinct pharmacological profiles observed after their microinjection in the nucleus accumbens and in the VTA is discussed.
Collapse
Affiliation(s)
- F Checler
- Institut de Pharmacologie Moléculaire et Cellulaire du CNRS, Valbonne, France
| | | | | | | |
Collapse
|
42
|
Fried G, Franck J, Brodin E, Terenius L. Subcellular distribution of two enzymes with neuropeptide converting activity in rat spinal cord. Neurochem Int 1991. [DOI: 10.1016/0197-0186(91)90004-w] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
43
|
Yoshida T, Nosaka S. Some characteristics of a peptidyl dipeptidase (kininase II) from rat CSF: differential effects of NaCl on the sequential degradation steps of bradykinin. J Neurochem 1990; 55:1861-9. [PMID: 2172462 DOI: 10.1111/j.1471-4159.1990.tb05769.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Incubation of various authentic peptides with rat CSF in vitro and analysis of their products by HPLC demonstrated the presence in CSF of a peptidyl dipeptidase [peptidyl dipeptide hydrolase; angiotensin I converting enzyme (ACE); kininase II; EC 3.4.15.1] which sequentially degraded bradykinin (BK) by liberating the carboxy-terminal dipeptides and converted angiotensin I to angiotensin II. This CSF enzyme was gel-chromatographed by means of HPLC, and the molecular weight was estimated. The susceptibility to various peptidase inhibitors of the rat CSF enzyme, as well as the effect of NaCl on the degradation of BK and Hip-His-Leu catalyzed by it, was also determined. These properties were compared with those of ACE or kininase II from brain or other tissues, as described in the literature. NaCl was shown to exert specific and concentration-dependent effects on each step of the sequential degradation of BK, via BK(1-7) to BK(1-5), catalyzed by the enzyme. In addition, the enzyme system for metabolism of BK appears to differ between rat CSF and blood, the former containing exclusively kininase II, whereas the latter contains both kininase I (carboxypeptidase N; EC 3.4.12.7) and kininase II.
Collapse
Affiliation(s)
- T Yoshida
- Department of Physiology, Mie University School of Medicine, Japan
| | | |
Collapse
|
44
|
Hooper NM. Angiotensin converting enzyme: how reliable is the fluorimetric assay with benzoyl-Gly-His-Leu as substrate? Biochem J 1990; 270:840-1. [PMID: 2173556 PMCID: PMC1131814 DOI: 10.1042/bj2700840] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
|
45
|
Matucci-Cerinic M, Pignone A, Iannone F, Lotti T, Pesciullesi E, Spillantini G, Falcini F, Cagnoni M. Clinical correlations of plasma angiotensin converting enzyme (ACE) activity in systemic sclerosis: a longitudinal study of plasma ACE level, endothelial injury and lung involvement. Respir Med 1990; 84:283-7. [PMID: 2173047 DOI: 10.1016/s0954-6111(08)80054-6] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Lung involvement was studied by perfusion scan, ventilation scan, pulmonary clearance rate of 99mTc DTPA and pulmonary function tests in 20 patients with systemic sclerosis (SSc). Decreased plasma angiotensin converting enzyme (ACE) activity and increased levels of von Willebrand Factor Antigen (vWF:Ag) were found in all patients with SSc. The relationship between ACE levels and lung involvement was not statistically significant, however levels of vWF:Ag correlated with parameters of lung vascular alterations. An inverse relationship between the reduced ACE levels and ESR was found. It is likely that ACE levels reflect the inflammatory aspect of the disease. Further studies of ACE synthesis, release and inhibition are needed to determine the mechanism of the observed decreased activity in SSc.
Collapse
Affiliation(s)
- M Matucci-Cerinic
- Istituto di Clinica Medica IV, Patologia Medica I, Universita di Firenze, Italy
| | | | | | | | | | | | | | | |
Collapse
|
46
|
Nunes-Mamede ML, De Mello FG, Martins AR. In ovo and in culture development of chick retinal angiotensin converting enzyme. Neurosci Lett 1990; 109:174-9. [PMID: 2156192 DOI: 10.1016/0304-3940(90)90558-q] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
The activity of angiotensin I-converting enzyme (ACE, EC 3.4.15.1), measured using Hip-His-Leu as substrate, was determined in the developing chick retina, and in monolayer and aggregate cultures of embryonic retinal cells. ACE specific activity in chick retinal homogenate increased 86-fold from embryonic day 13 until the 7th post-hatching day. The development of ACE activity occurred in parallel with that reported for synapse and photoreceptors. ACE activity expression in aggregates, but not in monolayer culture, was similar to that observed in the developing retina in ovo. At culture, day 13, ACE specific activity was 11.8-fold higher in the aggregate than in the dispersed cell culture, and was comparable to that in a 21-day-old embryonic intact retina. Our results suggest that histotypic association of retinal cells during development may be an important event controlling the expression of ACE activity in the CNS.
Collapse
Affiliation(s)
- M L Nunes-Mamede
- Departamento de Farmacologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Brazil
| | | | | |
Collapse
|
47
|
Robinson EL, Greenfield SA. The effect of captopril on the membrane properties of central neurons in-vitro. J Pharm Pharmacol 1990; 42:20-5. [PMID: 1969944 DOI: 10.1111/j.2042-7158.1990.tb05342.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Captopril, a potent antihypertensive that acts via inhibition of angiotensin converting enzyme also has apparent central actions. Its effects on membrane properties on particular central neurons in-vitro has therefore been investigated. In the substantia nigra, where there is a high concentration of angiotensin converting enzyme, captopril caused a dose-dependent depolarization without any apparent change in conductance, but possibly requiring the integrity of the dendritic arbour. A similar effect occurred when captopril was applied to neurons in either the thalamus or hippocampus, where levels of angiotensin converting enzyme are relatively low. Further studies with homologues of captopril revealed that the -SH group on the molecule was a prerequisite of the effect observed. It is concluded that the -SH group on the captopril molecule has an electrogenic effect on diverse central neurons, independent of inhibition of angiotensin converting enzyme, but preferentially manifest at the level of the dendrite.
Collapse
Affiliation(s)
- E L Robinson
- University Department of Pharmacology, Oxford, UK
| | | |
Collapse
|
48
|
Nunes-Mamede ML, De Mello FG, Martins AR. Effect of p-mercuribenzoate on the subestimation of angiotensin-converting enzyme measurement during chick retina development. J Neurosci Methods 1990; 31:7-11. [PMID: 2155360 DOI: 10.1016/0165-0270(90)90003-x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
The time course of dipeptidase activity and the effect of p-mercuribenzoate (PCMB) on the subestimation of the fluorometric determination of angiotensin-converting enzyme (ACE, EC 3.4.15.1) during development was studied. ACE and dipeptidase activities were measured fluorometrically in homogenates of the developing chick retina using Hip-His-Leu and His-Leu as substrates, respectively, both either in the presence or in the absence of 1 mM PCMB. ACE activity was inhibited by captopril (IC50 1.7 nM), MK 422 (IC50 4.8 nM), BPP9a (IC50 0.25 microM) and BPP5a (IC50 1.2 microM), thus suggesting that avian retinal ACE catalytically resembles the mammalian enzyme. Dipeptidase activity varied 3.4-fold throughout development, leading to a large and variable (28-83%) subestimation of ACE activity during chick retina ontogenesis. PCMB (1 mM) inhibited 67-94% dipeptidase activity during development, thus greatly reducing any subestimation of ACE activity determination during the development of the chick retina.
Collapse
Affiliation(s)
- M L Nunes-Mamede
- Departamento de Farmacologia, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Brasil
| | | | | |
Collapse
|
49
|
Abstract
C6 of rat glioma cells and their plasma membranes degrade substance P (SP). The degradation, occurring mainly through the cleavage of the Gln6-Phe7, Phe7-Phe8, and Gly9-Leu10 bonds, was strongly inhibited by phosphoramidon. Endopeptidase-24.11 (EC 3.4.24.11) purified from C6 cell membranes also cleaved SP at the same three peptide bonds in a manner sensitive to phosphoramidon. Thus, the degradation of SP by glioma cells and their membranes seems to be mediated by the action of endopeptidase-24.11.
Collapse
Affiliation(s)
- S Endo
- Department of Biochemistry, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
| | | | | |
Collapse
|
50
|
Abstract
Bradykinin (BK) (Arg1-Pro2-Pro3-Gly4-Phe5-Ser6-Pro7-Phe8-Arg9) was degraded by rat brain synaptic membranes at a rate comparable to that found for Met-enkephalin, but approximately 40 times the rate for vasopressin and oxytocin. The catabolic pathway for BK and its metabolites was elucidated through the use of high performance liquid chromatography for metabolite identification and peptidase inhibitors for blocking specific cleavage sites. BK was hydrolyzed at three sites: at the -Phe5-Ser6- bond by metalloendopeptidase 24.15, at the -Pro7-Phe8- bond by an apparently novel peptidyl dipeptidase, and at the -Phe8-Arg9 bond by a carboxypeptidase B-like enzyme. Each enzyme contributed about equally to BK degradation under the assay conditions used. Some of the resulting metabolites were further hydrolyzed: BK(1-8) to BK(1-7) + Phe by a DFP inhibitable prolyl carboxypeptidase-like enzyme, BK(1-8) to BK(1-5) + BK(6-8) by metalloendopeptidase 24.15, BK(1-7) slowly to BK(1-5) by a second peptidyl dipeptidase which was captopril inhibited, and Phe-Arg to Phe + Arg by a bestatin-inhibited dipeptidase. A number of properties of the individual enzymes were determined including sensitivity to a variety of peptidase inhibitors. These results provide a starting point for investigating the potential physiological role of each enzyme in BK function in the brain.
Collapse
Affiliation(s)
- A T Orawski
- Department of Biochemistry and Biophysics, Loyola University of Chicago Stritch School of Medicine, Maywood, IL 60153
| | | |
Collapse
|